Patents Assigned to Tillotts Pharma AG
-
Publication number: 20210030682Abstract: The present invention relates to a method for preparing immediate and sustained release solid dosage forms, comprising antibodies and functional fragments thereof, by solution/suspension layering,optionally coated with a delayed release coating; the solid dosage forms prepared by the method; and the use of the solid dosage forms in the topical treatment in the gastrointestinal tract of a patient.Type: ApplicationFiled: September 11, 2018Publication date: February 4, 2021Applicant: Tillotts Pharma AGInventors: Felipe VARUM, Laetitia VON ROCHOW, Carmen WETZEL, Roberto BRAVO
-
Patent number: 10799515Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: October 29, 2013Date of Patent: October 13, 2020Assignee: TILLOTTS PHARMA AGInventors: Felipe Jose Oliveira Varum, Roberto Carlos Bravo Gonzalez, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Publication number: 20200299375Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.Type: ApplicationFiled: March 16, 2017Publication date: September 24, 2020Applicant: Tillotts Pharma AGInventors: Tea GUNDE, Sebastian MEYER, Esther Maria FURRER
-
Publication number: 20200277367Abstract: The present invention relates to antibodies which bind to TNF? and comprise a modified Fc region. The antibodies of the invention have improved resistance against proteolytic degradation and good effector functions and/or pharmacokinetic properties.Type: ApplicationFiled: September 11, 2018Publication date: September 3, 2020Applicant: Tillotts Pharma AGInventor: Esther Maria FURRER
-
Publication number: 20200268675Abstract: The present invention relates to a method for preparing immediate and sustained release solid dosage forms, comprising antibodies and functional fragments thereof, by wet granulation, extrusion and spheronization,optionally coated with a delayed release coating the solid dosage forms prepared by the method and the use of the solid dosage forms in the topical treatment in the gastrointestinal tract of a patient.Type: ApplicationFiled: September 11, 2018Publication date: August 27, 2020Applicant: Tillotts Pharma AGInventors: Felipe VARUM, Sophie DECOLLOGNY, Roberto BRAVO
-
Publication number: 20200216527Abstract: The present invention relates to antibodies which bind to TNF? and exhibit modified FcRn-binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.Type: ApplicationFiled: September 11, 2018Publication date: July 9, 2020Applicant: Tillotts Pharma AGInventor: Esther Maria FURRER
-
Publication number: 20200214987Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: ApplicationFiled: March 18, 2020Publication date: July 9, 2020Applicant: Tillotts Pharma AGInventors: Felipe José OLIVEIRA VARUM, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Publication number: 20200170956Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.Type: ApplicationFiled: April 26, 2018Publication date: June 4, 2020Applicants: Tillotts Pharma AG, University College LondonInventors: Vipul YADAV, Abdul Waseh BASIT, Felipe José OLIVEIRA VARUM, Roberto Carlos BRAVO GONZALÉZ, Esther Maria FURRER
-
Publication number: 20190336449Abstract: The present invention relates to a multiple unit dosage form comprising a core, wherein the core comprises a plurality of individual units, each unit comprising a pharmaceutically active ingredient and each unit being covered with a mucoadhesive material, and wherein the multiple unit dosage form further comprises an enteric core coating layer. The invention furthermore relates to the use of said multiple unit dosage form in the treatment of inflammatory disorders, especially for the gastrointestinal tract.Type: ApplicationFiled: June 12, 2017Publication date: November 7, 2019Applicant: Tillotts Pharma AGInventors: Felipe VARUM, Roberto BRAVO, Daniel PREISIG
-
Patent number: 10391061Abstract: The present invention relates to a delayed release pharmaceutical formulation for delivering an active agent to the intestine, a method of preparing such formulation and the use of such formulation in the treatment of gastrointestinal disorders.Type: GrantFiled: January 9, 2018Date of Patent: August 27, 2019Assignee: Tillotts Pharma AGInventors: Daniel Preisig, Maxim Puchkov, Joerg Huwyler, Felipe José Oliveira Varum, Roberto Carlos Bravo Gonzalez
-
Patent number: 10272048Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralized, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: September 16, 2016Date of Patent: April 30, 2019Assignee: Tillotts Pharma AGInventors: Felipe Josè Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Patent number: 10226430Abstract: Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an inner layer and an outer layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralized polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base.Type: GrantFiled: April 29, 2013Date of Patent: March 12, 2019Assignee: TILLOTTS PHARMA AGInventors: Roberto Carlos Bravo Gonzalez, Thomas Buser, Frederic Jean-Claude Goutte, Abdul Waseh Basit, Felipe Jose Oliveira Varum, Ana Cristina Freire
-
Patent number: 10179105Abstract: The present invention relates to microgel particles containing nanotubes loaded with an active pharmaceutical ingredient, a process for their preparation and a pharmaceutical composition comprising the same.Type: GrantFiled: March 21, 2016Date of Patent: January 15, 2019Assignee: Tillotts Pharma AGInventors: Jan Kendall De Kruif, Carla Garofalo, Gisela Ledergerber, Martin Kuentz, Roberto Carlos Bravo Gonzaléz, Felipe José Oliveira Varum
-
Publication number: 20180125784Abstract: The present invention relates to a delayed release pharmaceutical formulation for delivering an active agent to the intestine, a method of preparing such formulation and the use of such formulation in the treatment of gastrointestinal disorders.Type: ApplicationFiled: January 9, 2018Publication date: May 10, 2018Applicant: Tillotts Pharma AGInventors: Daniel Preisig, Maxim Puchkov, Joerg Huwyler, Felipe José Oliveira Varum, Roberto Carlos Bravo Gonzalez
-
Publication number: 20180049980Abstract: The present invention relates to microgel particles, a process for their preparation and a pharmaceutical composition comprising the same.Type: ApplicationFiled: March 21, 2016Publication date: February 22, 2018Applicant: Tillotts Pharma AGInventors: Jan Kendall DE KRUIF, Carla GAROFALO, Gisela LEDERGERBER, Martin KUENTZ, Roberto Carlos BRAVO GONZALÉZ, Felipe José OLIVEIRA VARUM
-
Patent number: 9895314Abstract: The present invention relates to a delayed release pharmaceutical formulation for delivering an active agent to the intestine, a method of preparing such formulation and the use of such formulation in the treatment of gastrointestinal disorders, wherein the formulation includes at least one active agent associated with porous, functionalized calcium carbonate carrier particles that are surrounded by a material for colon targeting.Type: GrantFiled: September 22, 2014Date of Patent: February 20, 2018Assignee: Tillotts Pharma AGInventors: Daniel Preisig, Maxim Puchkov, Joerg Huwyler, Felipe José Oliveira Varum, Roberto Carlos Bravo Gonzalez
-
Patent number: 9814681Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: October 29, 2013Date of Patent: November 14, 2017Assignee: Tillotts Pharma AGInventors: Felipe José Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser
-
Publication number: 20170119681Abstract: The present invention relates to a modified release coated capsule and a process to obtain that capsule.Type: ApplicationFiled: May 13, 2015Publication date: May 4, 2017Applicant: TILLOTTS PHARMA AGInventors: Roberto Carlos BRAVO GONZALÉZ, Felipe José OLIVEIRA VARUM, Thomas BUSER
-
Publication number: 20170079927Abstract: The present invention relates to a modified release coated capsule and a process to obtain that capsule.Type: ApplicationFiled: May 13, 2015Publication date: March 23, 2017Applicant: Tillotts Pharma AGInventors: Roberto Carlos BRAVO GONZALÉZ, Felipe José OLIVEIRA VARUM, Thomas BUSER
-
Publication number: 20170035698Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: ApplicationFiled: September 16, 2016Publication date: February 9, 2017Applicant: Tillotts Pharma AGInventors: Felipe Josè OLIVEIRA VARUM, Roberto Carlos BRAVO GONZÁLEZ, Thomas BUSER, Abdul Waseh BASIT, Ana Cristina FREIRE